β-Elemene, an anticancer agent, was isolated from the traditional Chinese medicine plant, curcuma aromatica. In this study, we investigated the synergistic antitumor effect of β-elemene and etoposide phosphate (VP-16) in A549 non-small cell lung carcinoma cells. The cells were treated with β-elemene (20 or 50 µg/ml), VP-16 (15 µg/ml) or the combination of both for 24 h. Compared to the treatment with β-elemene or VP-16 alone, an increased antitumor activity was observed with the combination of both, which was mediated by the cleavage of PARP, the up-regulation of Bax, p53 and p21, and the suppression of cyclin D1. These results suggest that the combination of β-elemene and VP-16 may be a promising therapeutic option for lung cancer.
"Chen et al. (2012) reported b-elemene as an important anticancer drug and suggest its use in reducing the side effects of chemotherapy. The antitumor effect of b-elemene was the research subject of many authors (Yang et al. 1997; Wang et al. 2005; Sun et al. 2009; Liu et al. 2011; Zhang et al. 2011; Li et al. 2013). The presence of b-elemene and D-limonene in extracts of L. ventricosa can be good starting point for further investigation of antimicrobial activity of this species. "
[Show abstract][Hide abstract] ABSTRACT: The chemical composition of the methanolic and ethyl acetate extracts of liverwort Lophozia ventricosa (Dicks.) Dumort. was determined by solid phase microextraction-gas chromatography mass spectrometry (SPME-GC/MS). The dominant compounds in L. ventricosa methanolic extract were o-cymene (38.87 %), β-barbatene (26.35 %), and α-barbatene (8.30 %), while the main components in ethyl acetate extract were β-barbatene (45.39 %), maalioxide (9.89 %), and α-barbatene (8.21 %). The antimicrobial activity of L. ventricosa extracts was evaluated against 15 pathogenic microorganisms using microdilution method. Extracts were initially screened against following Gram (−) bacteria Enterobacter cloacae,
Pseudomonas aeruginosa, Salmonella typhimurium, and Gram (+) bacteria: Bacillus cereus, Listeria monocytogenes, Micrococcus flavus, and Staphylococcus aureus. The minimum inhibitory concentration (MIC) varied from 2.50 to 5.00 mg/mL for bacterial strains, and from 1.25 to 5.00 mg/mL for micromycetes. For the antifungal bioassays, eight fungi were used Aspergillus niger, A. fumigates, A. ochraceus, A. versicolor, Penicillium funiculosum, P. ochrochloron, Trichoderma viride, and Candida albicans. Sensitivity of fungi to the effect of the extracts was higher than that of bacteria tested.
"Thus, to investigate the therapeutic effect and safety, some researchers focused on studying the combination form of β-elemene and some chemotherapeutic agents. Synergistic antitumor effect of β-elemene (20 or 50 μg/mL) and etoposide (15 μg/mL) to A549 NSCLC has been observed by Zhang et al. , which was mediated by the cleavage of PARP, the upregulation of Bax, p53 and p21, as well as the suppression of cyclin D1. In addition, studies  have shown that β-elemene could eliminate the resistance of NSCLS cells to Gefitinib. "
[Show abstract][Hide abstract] ABSTRACT: In the past decade, β-elemene played an important role in enhancing the effects of many anticancer drugs and was widely used in the treatment of different kinds of malignancies and in reducing the side effects of chemotherapy. Further study showed that it is also a promising anti-lung cancer drug. However, the clinical application of β-elemene was limited by its hydrophobic property, poor stability, and low bioavailability. With the development of new excipients and novel technologies, plenty of novel formulations of β-elemene have improved dramatically, which provide a positive perspective in terms of clinical application for β-elemene. Liposome as a drug delivery system shows great advantages over traditional formulations for β-elemene. In this paper, we summarize the advanced progress being made in anti-lung cancer activity and the new liposomes delivery systems of β-elemene. This advancement is expected to improve the level of pharmacy research and provide a stronger scientific foundation for further study on β-elemene.
Evidence-based Complementary and Alternative Medicine 11/2012; 2012:259523. DOI:10.1155/2012/259523 · 1.88 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Herbal plants are enriched with compounds with a wide range of biological activities. Furanodiene is a sesquiterpene isolated from Rhizoma Curcumae. Growing evidence shows furanodiene exhibits diversified activities of hepatoprotection, anti-inflammation, anti-angiogenesis, and anti-tumor. However, its biological activities against breast cancer have not been deeply understood, and its potential as an anti-breast cancer agent combined with tamoxifen (TAM) has not been evaluated so far. This study describes the combined effects of furanodiene and TAM in human breast cancer cells in vitro. The results showed that ERa-negative MDA-MB-231 cells were much more sensitive than ERa-positive MCF-7 cells to the growth inhibition due to furanodiene. Combined administration of furanodiene and TAM led to marked increase in growth inhibition, cell cycle arrest and pro-apoptotic activity in ERa-positive cells compared to individual agent, and enhanced the down-regulation of p-cyclin D1, cyclin D1, CDK2, CDK6, p-Rb, Rb and p-p44, and the up-regulation of p27, Bax and Bad, but did not show increased cytotoxicity in ERa-negative MCF-10A non-tumorigenic breast epithelial cells. Co-incubation induced the typical PARP cleavage or caspase 9 cleavages compared to individual agent. In addition, PPARγ activity inhibition by its antagonist T0070907 did not significantly reverse the enhanced effect of furanodiene and TAM suggesting that anti-cancer properties of combination were PPARγ independent. Our data indicated that furanodiene could enhance the growth inhibitory and pro-apoptotic activity of TAM by inducing cell cycle arrest and cell apoptosis via CDKs-cyclins and mitochondria-caspases-dependent, and PPARγ-independent signaling pathways in breast cancer cells, without contributions to the cytotoxicity of TAM.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.